Citation Impact
Citing Papers
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
2000 Standout
Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
2010
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
2013
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
1991
Targeting hypoxia in cancer therapy
2011 Standout
Megestrol Acetate Stimulates Weight Gain and Ventilation in Underweight COPD Patients
2002
Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models
2005
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma
2002
PARP inhibitor combination therapy
2016
Rethinking amide bond synthesis
2011 StandoutNature
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
2000
A phase II evaluation of cisplatin and 5-Fluorouracil in patients with advanced squamous cell carcinoma of the cervix: A gynecologic oncology group study
1989
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Renal-Cell Carcinoma
1996 Standout
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
1993
Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
1993
Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography
1993
Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission.
1991
Hodgkin Disease: Prediction of Outcome with67Ga Scintigraphy after One Cycle of Chemotherapy
1999
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Treatment of Non-Hodgkin's Lymphoma
1993
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma
2000
Degradation of the drug sodium diclofenac by Trametes versicolor pellets and identification of some intermediates by NMR
2009
1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity
2007
Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
2012
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease
2006
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
2008
An overview on 5α-reductase inhibitors
2009
Power failure: why small sample size undermines the reliability of neuroscience
2013 Standout
Delta agonist hydroxy bioisosteres: The discovery of 3-((1-benzylpiperidin-4-yl){4-[(diethylamino)carbonyl]phenyl}amino)benzamide with improved delta agonist activity and in vitro metabolic stability
2009
Prevention of Venous Thromboembolism
2004 Standout
Inflammation and cancer: back to Virchow?
2001 Standout
DNA repair dysregulation from cancer driver to therapeutic target
2012
Primary brain tumours in adults
2012 Standout
Cancer Anorexia-Cachexia Syndrome: Current Issues in Research and Management
2002
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
2006
Reporting outcomes in Hodgkin's disease and lymphoma.
1987
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
2006
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
2005
Delayed reward discounting and addictive behavior: a meta-analysis
2011
Aldimine‐Directed Branched‐Selective Hydroarylation of Styrenes
2012
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma
2003
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Tumor Angiogenesis
2008 Standout
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
2016
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Cobalt-catalyzed Branched-selective Addition of Aromatic Ketimines to Styrenes under Room-temperature Conditions
2013
3d Transition Metals for C–H Activation
2018 Standout
Cobalt-Catalyzed, N–H Imine-Directed Hydroarylation of Styrenes
2018
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
2016
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
What's in Placebos: Who Knows? Analysis of Randomized, Controlled Trials
2010
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma.
1990
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
2010 Standout
The Hitchhiker’s Guide to Flow Chemistry
2017 Standout
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Mild metal-catalyzed C–H activation: examples and concepts
2016 Standout
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
2011 Standout
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Preparation of unsymmetrical biaryls via palladium-catalyzed coupling reaction of aryl halides
2001
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
1994
IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA
1993
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
2008 Standout
Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference
2007 StandoutNobel
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2004
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
2003 Standout
Pharmaceuticals of Emerging Concern in Aquatic Systems: Chemistry, Occurrence, Effects, and Removal Methods
2019 Standout
Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma
2007
Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen
1993
Soluble polyarylenes containing alternating binaphthylene and biphenylene structural units
1992
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
1999 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines
1999
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
Biology of Cachexia
1997
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.
1997
Enzyme-Controlled Nitrogen-Atom Transfer Enables Regiodivergent C–H Amination
2014 StandoutNobel
1,1‘-Binaphthyl Dimers, Oligomers, and Polymers: Molecular Recognition, Asymmetric Catalysis, and New Materials
1998 Standout
Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer
1999
Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia
1997
Works of Patrick S. Johnson being referenced
Pathological gamblers discount probabilistic rewards less steeply than matched controls.
2009
Highly potent and selective zwitterionic agonists of the δ-opioid receptor. Part 1
2005
Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia
1990
Phase II Studies of Bleomycin, Cyclophosphamide, Doxorubicin and Cisplatin, and Bleomycin and Cisplatin in Advanced Cervical Carcinoma
1988
Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantation
1989
A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma.
1991
Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia
1997
Designing rapid onset selective serotonin re-uptake inhibitors. 2: Structure–activity relationships of substituted (aryl)benzylamines
2008
A Randomized Phase II and Pharmacokinetic Study of Dacarbazine in Patients with Recurrent Glioma
2000
Bolus Versus Infusion Regimens of Etoposide and Cisplatin in Treatment of Non-Small Cell Lung Cancer: A Study of the North Central Cancer Treatment Group
1990
Microbial oxidative metabolism of diclofenac: production of 4′-hydroxydiclofenac using Epiccocum nigrum IMI354292
1998
Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure–activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine
2005
896. The quantitative study of the arylation of naphthalene by means of diazonium salt and zinc. Part II
1962
Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.
1986
The development of non-steroidal dual inhibitors of both human 5α-reductase isozymes
1996
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
2008